MF
PTCT icon

Magnetar Financial’s PTC Therapeutics PTCT Stock Holding History

Magnetar Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,302
Closed -$646K – 1797
2022
Q1 		$646K Buy
+17,302
New +$667K 0.01% 877
2021
Q3 		– Sell
-24,455
Closed -$1.03K – 1486
2021
Q2 		$1.03K Buy
+24,455
New +$1.05M 0.01% 711
2020
Q4 		– Sell
-10,268
Closed -$480K – 859
2020
Q3 		$480K Buy
+10,268
New +$506K 0.01% 453

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Magnetar Financial's PTCT Position: Q2 2022 in Review

Magnetar Financial sold out of PTC Therapeutics (PTCT) in Q2 2022, closing a stake of 17,302 shares — an estimated $646K sold.

Magnetar Financial first reported a position in PTCT in Q3 2020 and held it in 3 quarters. The position peaked at $646K in Q1 2022. 180 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

  • Magnetar Financial reported no remaining PTC Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Magnetar Financial sold 17,302 PTC Therapeutics shares in Q2 2022, an estimated $646K.
  • Magnetar Financial first reported a position in PTC Therapeutics in Q3 2020 and held it in 3 quarters.
  • Magnetar Financial's PTC Therapeutics position peaked at $646K in Q1 2022.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Magnetar Financial's 13F filing for Q2 2022, filed 15 Aug 2022.